Marika Musielak , Paweł Bakun , Julia Liwarska , Paulina Skupin-Mrugalska , Igor Piotrowski , Wiktoria Suchorska
{"title":"Precision medicine in breast cancer: Targeting molecular subtypes with gold nanoparticle-loaded liposomes","authors":"Marika Musielak , Paweł Bakun , Julia Liwarska , Paulina Skupin-Mrugalska , Igor Piotrowski , Wiktoria Suchorska","doi":"10.1016/j.advms.2024.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Breast cancer is a complex disease with several molecular subtypes that respond differently to therapy. This paper describes liposomes loaded with gold nanoparticles as a targeted drug delivery method in the rapidly developing precision breast cancer treatment area. The aim was to investigate the cytotoxicity level and cellular uptake using several breast cancer cell lines and a normal breast cell line.</p></div><div><h3>Materials and methods</h3><p>We synthesized gold nanoparticles incorporated in liposomes. Nanostructures were incubated with breast cancer cell lines of different subtypes. The analysis included MTT assay, flow cytometry and immunofluorescence.</p></div><div><h3>Results</h3><p>Cell viability varied among different cancer cells. Moreover, the time- and concentration-dependent manner of viability change was observed. The internalization of liposomes with gold nanoparticles and nanoparticles alone determined different results depending on molecular breast cancer subtypes. The luminal B and triple-negative breast cancer cells demonstrated the highest resistance and sensitivity, respectively. The intensity of cells’ interaction with the proposed nanostructures was observed in both cell lines. In this study, we compare the molecular subtypes of breast cancer and discuss how this novel method might improve the therapy success.</p></div><div><h3>Conclusions</h3><p>Our research sheds light on the possibility of new individualized treatments for breast cancer patients, opening the path for better results and a more detailed cancer therapy strategy.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"69 2","pages":"Pages 331-338"},"PeriodicalIF":2.5000,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112624000397","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Breast cancer is a complex disease with several molecular subtypes that respond differently to therapy. This paper describes liposomes loaded with gold nanoparticles as a targeted drug delivery method in the rapidly developing precision breast cancer treatment area. The aim was to investigate the cytotoxicity level and cellular uptake using several breast cancer cell lines and a normal breast cell line.
Materials and methods
We synthesized gold nanoparticles incorporated in liposomes. Nanostructures were incubated with breast cancer cell lines of different subtypes. The analysis included MTT assay, flow cytometry and immunofluorescence.
Results
Cell viability varied among different cancer cells. Moreover, the time- and concentration-dependent manner of viability change was observed. The internalization of liposomes with gold nanoparticles and nanoparticles alone determined different results depending on molecular breast cancer subtypes. The luminal B and triple-negative breast cancer cells demonstrated the highest resistance and sensitivity, respectively. The intensity of cells’ interaction with the proposed nanostructures was observed in both cell lines. In this study, we compare the molecular subtypes of breast cancer and discuss how this novel method might improve the therapy success.
Conclusions
Our research sheds light on the possibility of new individualized treatments for breast cancer patients, opening the path for better results and a more detailed cancer therapy strategy.
目的：乳腺癌是一种复杂的疾病，有多种分子亚型，对治疗的反应各不相同。本文介绍了在快速发展的乳腺癌精准治疗领域中作为靶向给药方法的金纳米粒子脂质体。目的是利用几种乳腺癌细胞系和一种正常乳腺癌细胞系研究细胞毒性水平和细胞吸收情况：我们在脂质体中合成了金纳米颗粒。将纳米结构与不同亚型的乳腺癌细胞系培养。分析包括 MTT 试验、流式细胞术和免疫荧光：结果：不同癌细胞的细胞活力各不相同。结果：不同癌细胞的存活率各不相同，而且存活率的变化与时间和浓度有关。根据乳腺癌分子亚型的不同，脂质体与金纳米颗粒和单独纳米颗粒的内化结果也不同。管腔 B 型和三阴性乳腺癌细胞分别表现出最高的抗药性和敏感性。在这两种细胞系中都观察到了细胞与所提出的纳米结构相互作用的强度。在这项研究中，我们比较了乳腺癌的分子亚型，并讨论了这种新方法如何提高治疗成功率：我们的研究揭示了为乳腺癌患者提供新型个体化治疗的可能性，为获得更好的治疗效果和更详细的癌症治疗策略开辟了道路。
期刊介绍：
Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines.
The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments.
Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines.
The journal welcomes submissions from the following disciplines:
General and internal medicine,
Cancer research,
Genetics,
Endocrinology,
Gastroenterology,
Cardiology and Cardiovascular Medicine,
Immunology and Allergy,
Pathology and Forensic Medicine,
Cell and molecular Biology,
Haematology,
Biochemistry,
Clinical and Experimental Pathology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
